Trials / Completed
CompletedNCT02159599
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Fundacion SEIMC-GESIDA · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label randomized clinial trial to evaluate the treatment with darunavir/ritonavir (800mg/100mg) plus lamivudine (300 mg) once daily versus continuing with darunavir/ritonavir (800mg/100mg) once daily plus tenofovir/emtricitabine (300mg/200mg) or abacavir/lamivudine (600mg/300mg) in HIV infected subject with suppressed plasma viremia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Darunavir/Ritonavir | Darunavir/ritonavir (800/100 mg): QD (quaque die ) |
| DRUG | Lamivudine | Lamivudine (300mg) : QD |
| DRUG | Emtricitabine/tenofovir or abacavir/lamivudine | Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-06-10
- Last updated
- 2017-02-14
Locations
21 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02159599. Inclusion in this directory is not an endorsement.